Genomes and Genes
William T Hu
Affiliation: Emory University
- CSF complement 3 and factor H are staging biomarkers in Alzheimer's diseaseWilliam T Hu
Department of Neurology, Emory University School of Medicine, 615 Michael Street, 505 F, Atlanta, GA, 30322, USA
Acta Neuropathol Commun 4:14. 2016..We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status...
- Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosisWilliam T Hu
Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America
PLoS ONE 8:e57584. 2013..It is difficult to longitudinally characterize cognitive impairment in amyotrophic lateral sclerosis (ALS) due to motor deficits, and existing instruments aren't comparable with assessments in other dementias...
- Plasma multianalyte profiling in mild cognitive impairment and Alzheimer diseaseWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 79:897-905. 2012..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
- Biomarkers in frontotemporal lobar degenerations--progress and challengesWilliam T Hu
Department of Neurology, Center for Neurodegenerative Diseases, Emory University, Atlanta, GA 30322, USA
Prog Neurobiol 95:636-48. 2011..Given the pathologic overlap of FTLD with ALS and PSP, collaboration with specialists in those fields will be essential in the translation of promising FTLD biomarkers into clinical practice...
- Plasma epidermal growth factor levels predict cognitive decline in Parkinson diseaseAlice S Chen-Plotkin
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Ann Neurol 69:655-63. 2011..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseasesJon B Toledo
Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
Acta Neuropathol 124:23-35. 2012....
- Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Acta Neuropathol 119:669-78. 2010..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone...
- Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's diseaseKeith A Josephs
Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
Mov Disord 25:1246-52. 2010..In subjects presenting with CBS, prominent temporoparietal, especially posterior temporal and inferior parietal, atrophy may be a clue to the presence of underlying AD pathology...
- Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDPWilliam T Hu
From the Department of Neurology W T H, K W, J G, J J L, C H, M S, A I L, Center for Neurodegenerative Diseases Research W T H, K W, J G, J J L, C H, A I L, Alzheimer s Disease Research Center W T H, J G, J J L, C H, A I L, Emory University School of Medicine, Atlanta, GA and Departments of Neurology M G and Laboratory Medicine and Pathology V V D, J Q T, University of Pennsylvania, Philadelphia
Neurology 81:1945-52. 2013....
- Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosisRyan Vass
Department of Neurology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
Acta Neuropathol 121:373-80. 2011..These findings implicate the FTLD-TDP risk gene TMEM106B in the development of cognitive impairment in ALS...
- Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's diseaseWilliam T Hu
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Acta Neuropathol 120:385-99. 2010....
- Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementiaWilliam T Hu
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Alzheimer Dis Assoc Disord 21:S39-43. 2007..In summary, survival in 4R tauopathies seemed independent of the presenting clinical phenotype, and there may be subtle clinical differences between bv-FTD patients with 3R and 4R tauopathies...
- Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndromeWilliam T Hu
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
Mov Disord 24:1375-9. 2009..AD patients with clinical CBS have similar characteristics to CBD patients. Functional brain imaging may have greater utility than the clinical and neuropsychological features in differentiating AD presenting as CBS from CBD...
- Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer diseaseWilliam T Hu
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Acta Neuropathol 116:215-20. 2008..The distribution of the lesions in this cross-sectional analysis may suggest a progression of TDP-43 pathology in AD, with limbic structures in the medial temporal lobe affected first, followed by higher order association cortices...
- TDP-43 and frontotemporal dementiaWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19106, USA
Curr Neurol Neurosci Rep 9:353-8. 2009....
- Survival profiles of patients with frontotemporal dementia and motor neuron diseaseWilliam T Hu
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
Arch Neurol 66:1359-64. 2009..Frontotemporal dementia and amyotrophic lateral sclerosis are neurodegenerative diseases associated with TAR DNA-binding protein 43- and ubiquitin-immunoreactive pathologic lesions...
- From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkersChadwick M Hales
Department of Neurology, Emory Alzheimer s Disease Research Center and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia, USA
Int Rev Psychiatry 25:210-20. 2013..Finally we will highlight future directions in the FTD field. More research is needed to elucidate the cellular mechanisms of neurodegeneration in FTLD and improve clinical diagnostic capabilities...
- Clinical features of pathologic subtypes of behavioral--variant frontotemporal dementiaWilliam T Hu
Department of Neurology, Mayo Clinic College of Medicine, Rochester MN, USA
Arch Neurol 64:1611-6. 2007..To identify clinical features in behavioral-variant frontotemporal dementia that may help predict tau-positive pathology...
- Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's diseaseZhentao Zhang
1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA 2 Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China
Nat Med 20:1254-62. 2014..Together, these observations indicate that AEP acts as a crucial mediator of tau-related clinical and neuropathological changes. Inhibition of AEP may be therapeutically useful for treating tau-mediated neurodegenerative diseases. ..